Transduced CD34+ Cells

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
285	ファンコニ貧血	7

285. ファンコニ貧血

臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04248439 (ClinicalTrials.gov)	July 15, 2020	24/1/2020	Gene Therapy for Fanconi Anemia, Complementation Group A	A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduc ...	Fanconi Anemia Complementation Group A	Biological: RP-L102	Rocket Pharmaceuticals Inc.	NULL	Recruiting	1 Year	N/A	All	5	Phase 2	United States
2	EUCTR2018-002502-31-GB (EUCTR)	07/02/2020	08/10/2019	A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transdu ...	A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transdu ...	Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fancon ...	Product Code: RP-L102 INN or Proposed INN: CD34+CELLS Other descriptive name: CD34+CELLS	Rocket Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	5	Phase 2	Spain;United Kingdom
3	NCT04069533 (ClinicalTrials.gov)	November 28, 2019	23/8/2019	Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A	A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transdu ...	Fanconi Anemia Complementation Group A	Biological: RP-L102	Rocket Pharmaceuticals Inc.	NULL	Recruiting	1 Year	17 Years	All	5	Phase 2	Spain
4	NCT03814408 (ClinicalTrials.gov)	January 11, 2019	14/1/2019	A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype ...	A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced ...	Fanconi Anemia Complementation Group A	Biological: RP-L102	Rocket Pharmaceuticals Inc.	NULL	Active, not recruiting	1 Year	12 Years	All	2	Phase 1	United States
5	EUCTR2018-002502-31-ES (EUCTR)	31/10/2018	02/08/2018	A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transdu ...	A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transdu ...	Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fancon ...	Product Name: RP-L102 INN or Proposed INN: CD34+CELLS Other descriptive name: CD34+CELLS	Rocket Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	5	Phase 2	Spain
6	EUCTR2011-006100-12-ES (EUCTR)	12/04/2013	27/01/2012	Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of cells transducedw ...	Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ ...	Fanconi anemia (Subtype A) MedDRA version: 15.1;Level: LLT;Classification code 10055206;Term: Fancon ...	Product Name: CD34+ Cells INN or Proposed INN: CD34+ CELLS Other descriptive name: CD34+ CELLS	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	5	Phase 1	Spain
7	NCT00001399 (ClinicalTrials.gov)	December 3, 1993	3/11/1999	Gene Therapy for the Treatment of Fanconi's Anemia Type C	Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoieti ...	Fanconi's Anemia;Pancytopenia	Drug: Transduced CD34+ Cells	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	5 Years	N/A	All	9	Phase 1	United States

First Previous1Next Last